Explaining its stand yesterday in response to MediaCorp's queries, the HSA said it has reviewed studies that led to the discussion on this issue in the US and noted that the studies were conducted using Avastin in combination with another drug, docetaxel.
But in Singapore, the approved use for Avastin is in combination with the drug paclitaxel, for treatment of breast cancer that has spread to other parts of the body.
The approval in 2008 for this combinationwas based on the "significant improvement demonstrated with respect to delay in disease progression", said the HSA, which therefore found that the studies leading to the US debate could not be generalised.
The HSA also reviewed data to assess the risk-benefit profile of Avastin and had advised concerned patients to consult their doctors after the US FDA panel first ruled last December against the drug's use in breast cancer patients.
The outcome of the assessment remains favourable, said an HSA spokesperson: "On this basis, Avastin will remain as a treatment option for patients with metastatic breast cancer in Singapore."
In the US, Avastin is approved for multiple cancers and will still be available for breast cancer treatment, but insurers are expected to drop coverage if it loses the FDA's approval, according to wire news reports.